Silexan for treatment of anxiety and depression in the context of COVID-19.

导出 OA

翻译打印收藏纠错

第一作者： Lucie,Bartova

第一单位： Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

作者： Lucie,Bartova ^[1] ; Markus,Dold ^[1] ; Gernot,Fugger ^[2] ; Ana,Weidenauer ^[1] ; Dan,Rujescu ^[1] ; Siegfried,Kasper ^[3]

作者单位： Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria. ^[1] Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria; Psychiatric Day Hospital, University Hospital St. Poelten, St. Poelten, Austria; Karl Landsteiner Private University of Health Sciences, Krems an der Donau, Austria. ^[2] Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria; Center for Brain Research, Medical University of Vienna, Vienna, Austria. Electronic address: siegfried.kasper@meduniwien.ac.at. ^[3]

关键词 Anxiety COVID-19 Depression Psychosomatic Silexan Subsyndromal

主题词人类(Humans);抑郁(Depression);植物油类(Plant Oils);油类, 挥发(Oils, Volatile);焦虑(Anxiety)

DOI 10.1016/j.euroneuro.2023.02.015

PMID 36867894

发布时间 2023-05-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交